Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Intravenous Human Immunoglobulins Neutralizes Omicron Subvariants BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/BA.5 for Treatment of Coronavirus Disease 2019

Mayanka Awasthi; Hana Golding; Surender Khurana

doi:10.1093/cid/ciac642

Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Intravenous Human Immunoglobulins Neutralizes Omicron Subvariants BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/BA.5 for Treatment of Coronavirus Disease 2019

Clin Infect Dis. 2023 Feb 8;76(3):e503-e506. doi: 10.1093/cid/ciac642.

Authors

Mayanka Awasthi¹, Hana Golding¹, Surender Khurana¹

Affiliation

¹ Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.

Abstract

Our study demonstrates that neither 2020 convalescent plasma (CP) nor 2019/2020 intravenous immunoglobulin (IVIG) neutralizes Omicron subvariants BA.1 to BA.5. In contrast, 2020 hyperimmune anti-severe acute respiratory syndrome coronavirus 2 IVIG (hCoV-2IG) lots neutralized Omicron variants of concern, similar to results with 2022 CP from BA.1 breakthrough infections. Therefore, high-titer hCoV-2IG and CP could be evaluated for treatment of high-risk individuals infected with circulating Omicron subvariants.

Keywords: COVID-19; Convalescent Plasma; Omicron; Treatment; intravenous immunoglobulins.

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.

Publication types

Research Support, U.S. Gov't, P.H.S.

MeSH terms

COVID-19 Serotherapy
COVID-19*
Humans
Immunoglobulins, Intravenous* / therapeutic use
SARS-CoV-2

Substances

Immunoglobulins, Intravenous

Supplementary concepts

SARS-CoV-2 variants

Grants and funding

HH/HHS/United States